Injectable protocols deliver copper peptides systemically, affecting all tissues including those unreachable by topical application
Important Safety Information Do not use AOD-9604 if you: Have a known allergy to growth hormone fragments or any component of the formulation Have been diagnosed with active cancer or have a history of malignancy (use only under medical supervision) Are pregnant or breastfeeding (safety data is lacking) Have severe uncontrolled diabetes or metabolic disorders without medical supervision Common side effects may include: Injection site reactions, mild headaches, temporary fatigue, or slight dizziness during initial use
Eligible domestic US orders may be fulfilled from a US warehouse
For dietary deficiency where absorption is intact, oral B12 supplementation may be appropriate after initial loading doses
AOD-9604 offers a distinct, IGF-1-independent lipolysis mechanism worth studying in its own right
Across all categories, preserved diluents consistently outperform unpreserved alternatives when reconstituted vials must be sampled over a span of two or more weeks
